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The identification of transporters of the HIV integrase inhibitor raltegravir could be a factor in an under-
standing of the pharmacokinetic-pharmacodynamic relationship and reported drug interactions of raltegravir.
Here we determined whether raltegravir was a substrate for ABCB1 or the influx transporters SLCO1A2,
SLCO1B1, SLCO1B3, SLC22A1, SLC22A6, SLC10A1, SLC15A1, and SLC15A2. Raltegravir transport by
ABCB1 was studied with CEM, CEMVBL100, and Caco-2 cells. Transport by uptake transporters was assessed
by using a Xenopus laevis oocyte expression system, peripheral blood mononuclear cells, and primary renal
cells. The kinetics of raltegravir transport and competition between raltegravir and tenofovir were also
investigated using SLC22A6-expressing oocytes. Raltegravir was confirmed to be an ABCB1 substrate in CEM,
CEMVBL100, and Caco-2 cells. Raltegravir was also transported by SLC22A6 and SLC15A1 in oocyte expression
systems but not by other transporters studied. The Km and Vmax for SLC22A6 transport were 150 M and 36
pmol/oocyte/h, respectively. Tenofovir and raltegravir competed for SLC22A6 transport in a concentration-
dependent manner. Raltegravir inhibited 1 M tenofovir with a 50% inhibitory concentration (IC50) of 14.0
M, and tenofovir inhibited 1 M raltegravir with an IC50 of 27.3 M. Raltegravir concentrations were not
altered by transporter inhibitors in peripheral blood mononuclear cells or primary renal cells. Raltegravir is
a substrate for SLC22A6 and SLC15A1 in the oocyte expression system. However, transport was limited
compared to endogenous controls, and these transporters are unlikely to have a great impact on raltegravir
pharmacokinetics.
HIV infection and AIDS continue to be a major cause of
worldwide mortality in the 21st century. A UNAIDS/WHO
report in 2009 estimated that 33.4 million people worldwide
were infected with HIV in 2008, with AIDS-related deaths
numbering 2 million. Recent attempts to develop a vaccine for
HIV have been largely unsuccessful (18). This, combined with
increasing drug resistance, has emphasized the need to develop
new drugs with unique mechanisms of action.
Raltegravir represents a new class of antiretroviral treat-
ment (8), targeting the HIV-1 integrase enzyme by binding to
the active site and preventing viral DNA insertion into the host
genome (11). Recent trials have shown raltegravir to have a
sustained antiretroviral effect and good tolerability in treat-
ment-experienced HIV-1 patients (33). The primary route of
raltegravir metabolism is glucuronidation via UGT1A1, and
raltegravir is not a substrate or an inhibitor of the major cyto-
chrome P450 enzymes (19, 24). However, the involvement of
human drug transporters in raltegravir absorption, disposition,
metabolism, and excretion (ADME) has not been fully inves-
tigated. Raltegravir has been described as being an ABCB1
substrate (25), but there are no data yet in the public domain.
Raltegravir has shown higher concentrations (1.7-fold) in se-
men (4) and lower concentrations (0.04- to 0.39-fold) in cere-
brospinal fluid (7, 41) than in plasma, which may be facilitated
by drug transporters present at membrane barriers.
There are important reasons why raltegravir should be
screened for potential transport by known drug transporters.
First, by regulating intracellular permeation, drug transporters
could be an important factor in an understanding of the lack of
a clear pharmacokinetic-pharmacodynamic (PK-PD) relation-
ship of raltegravir, i.e., the similar virological response ob-
served for patients given a wide range of raltegravir doses (29).
Second, a knowledge of the mechanisms that control raltegra-
vir disposition may help rationalize or even anticipate drug-
drug interactions in the clinic. Since raltegravir represents the
first member of a new drug class, possessing a unique chemical
structure containing a diketo acid derivative (34), class-specific
trends in drug transport may be evident, such as those reported
previously for protease inhibitors with ABCB1 (26, 37) or
nucleoside reverse transcriptase inhibitors with organic anion
and cation transporters (35, 36). Finally, knowledge of which
transporters are involved in raltegravir ADME will identify
candidate genes for future pharmacogenetic studies.
There have been a number of studies undertaken to evaluate
the pharmacokinetic interactions between raltegravir and co-
administered drugs. Most studies have shown raltegravir me-
tabolism and disposition to be largely unaffected. For example,
etravirine (1), maraviroc (3), darunavir (2), and rifabutin (6)
had no or a relatively modest effect on raltegravir plasma
concentrations. In addition, despite ritonavir being an inducer
of both ABCB1 (9) and UGT1A1 (12), the drug caused only a
minimal reduction in the raltegravir plasma concentration
* Corresponding author. Mailing address: Department of Pharma-
cology and Therapeutics, University of Liverpool, 70 Pembroke Place,
Liverpool L69 3GF, United Kingdom. Phone: 44 (0) 151 794 5919. Fax:
44 (0) 151 794 5656. E-mail: aowen@liv.ac.uk.
 Published ahead of print on 15 November 2010.
879
(22). Similarly, tipranavir combined with ritonavir had little
impact on raltegravir pharmacokinetics (13). However, there
are interactions between raltegravir and coadministered drugs
that have a more marked effect on raltegravir disposition.
Atazanavir is an inhibitor of UGT1A1 (42), and the coad-
ministration of atazanavir (400 mg once a day [QD]) with
raltegravir (100 mg single dose) resulted in increased raltegra-
vir plasma area under the concentration-time curve (AUC),
Cmax, and Cmin values of 72%, 53%, and 95%, respectively
(20). This interaction was also confirmed in a separate study
(43). Efavirenz and rifampin are inducers of UGT1A1 expres-
sion (14, 40) and have been shown to decrease raltegravir
plasma exposure (22, 39). Other interactions were reported
previously for omeprazole (21) and fosamprenavir (28).
One intriguing interaction is that of tenofovir, causing a
moderate increase in the raltegravir AUC and Cmax by 49%
and 64%, respectively (38). Although the increase in the ralte-
gravir plasma concentration is unlikely to have any important
clinical significance (i.e., no increase in toxicity), the mecha-
nism of the interaction is currently unexplained. Interestingly,
tenofovir is an anionic compound when charged and is there-
fore a substrate of the organic anion uptake transporters
SLC22A6 and SLC22A8 (36).
The aim of this study was to confirm the transport of ralte-
gravir by ABCB1 (phosphoglycoprotein) and to investigate
potential transport by major human drug influx transporters
(25), with the exception of CNTs (concentrative nucleoside
transporters) and ENTs (equilibrative nucleoside transport-
ers), since these are specific to nucleotides. The influx trans-
porters characterized were SLCO1A2 (OATPA), SLCO1B1
(OATPC), SLCO1B3 (OATP8), SLC22A1 (OCT1), SLC22A6
(OAT1), SLC10A1 (NTCP), SLC15A1 (PEPT1), and
SLC15A2 (PEPT2). Since tenofovir is a substrate for
SLC22A6, the putative role for this transporter in the interac-
tion between raltegravir and tenofovir was also investigated.
MATERIALS AND METHODS
Chemical reagents used. CellFix was obtained from Becton Dickinson (Ox-
ford, United Kingdom). UIC2 (anti-ABCB1) antibody was obtained from Im-
munotech (Marseilles, France). The IgG2a negative control and goat anti-mouse
IgG2a-RPE (R-phycoerythrin) were obtained from Serotech Ltd. (Oxford,
United Kingdom). CEM and CEMVBL100 cells were donated by Ross Davey, Bill
Walsh Cancer Research Laboratories (St. Leonards, Australia). Caco-2 cells
were purchased from the European Collection of Cell Cultures (Salisbury,
United Kingdom). Primary renal proximal tubule epithelial cells, renal cell basal
medium, and renal cell growth kit components were purchased from the Amer-
ican Type Culture Collection. [3H]raltegravir (specific activity  32.85 Ci/mmol)
and nonradiolabeled raltegravir sodium salt were gifts from Merck. [3H]digoxin
(specific activity  40 Ci/mmol) was purchased from Perkin-Elmer. [3H]saquina-
vir (specific activity  0.2 Ci/mmol) and [3H]tenofovir (specific activity  3.4
Ci/mmol) were purchased from Moravek. [3H]estrone-3-sulfate (specific activ-
ity  50 Ci/mmol), [14C]tetraethyl ammonium (specific activity  55 mCi/mmol),
[3H]taurocholic acid (specific activity  10 Ci/mmol), [3H]glycyl sarcosine (spe-
cific activity  60 Ci/mmol), and [3H]aminohippuric acid (specific activity  5
Ci/mmol) were purchased from American Radiolabeled Chemicals. Tariquidar
was purchased from Xenova (Sloane, United Kingdom). Nonradiolabeled teno-
fovir was a gift from Gilead. Image clones of SLC22A6 and SLC22A8 were
purchased from Geneservice. Ficoll-Paque Plus was purchased from GE Health-
care (Buckinghamshire, United Kingdom). All other reagents were obtained
from Sigma (Poole, United Kingdom).
Cell culture. CEM and CEMVBL100 cells were maintained in cell culture
medium (RPMI 1640 medium, 10% [wt/vol] fetal calf serum [FCS]) prior to the
experiment (37°C in 5% CO2). CEM cells are a wild-type T-lymphoblastoid cell
line. CEMVBL100 cells are CEM cells that have greatly increased ABCB1 expres-
sion (selected using vinblastine up to a concentration of 100 ng/ml). Caco-2 cells
were maintained in cell culture by passaging at 70% confluence using cell culture
medium (Dulbecco’s modified Eagle’s medium [DMEM], 15% [wt/vol] FCS)
prior to the experiment (37°C in 5% CO2). Primary renal proximal tubule
epithelial cells were maintained in cell culture by passage at 95% confluence
using renal epithelial cell basal medium with essential components (0.5% [wt/vol]
FCS, 10 nM triiodothyronine, 10 ng/ml recombinant human epidermal growth
factor [rhEGF], 100 ng/ml hydrocortisone hemisuccinate, 5 g/ml rh insulin, 1
M epinephrine, 5 g/ml transferrin, 2.4 mM L-alanyl-L-glutamine) prior to the
experiment (37°C in 5% CO2).
Cytotoxicity testing. CEM and Caco-2 cell lines (100 l; 2  105 cells/ml) were
incubated in a 96-well Nunc flat-bottom plate (37°C in 5% CO2 for 120 h) with
0, 0.001, 0.01, 0.1, 1, 10, and 100 M raltegravir. To validate the study, the
cytotoxic control compounds epirubicin and vinblastine were incubated (0.1, 1,
10, and 100 M) with CEM and Caco-2 cells, respectively. Following incubation,
the plates were centrifuged (2,000 rpm for 5 min), and the supernatant was
discarded and replaced with a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide (MTT) solution (1 mg/ml MTT, 100 l Hanks balanced salt
solution [HBSS]). A standard MTT assay was performed, the mean absorption
was calculated for each raltegravir concentration (n  6), and results were
expressed as the percent absorbance compared to the vehicle control (30).
Confirmation of ABCB1 expression in CEM and CEMVBL100 cells by flow
cytometry. The expression of ABCB1 in CEM and CEMVBL100 cells was deter-
mined by using a Coulter Epics XL-MCL flow cytometer as previously described
(27). Results are given as relative fluorescence units (mean fluorescence minus
that of the isotype control; n  3)  standard deviations (SD).
Cellular accumulation of raltegravir in CEM and CEMVBL100 cells. CEM and
CEMVBL100 cells of a constant cell density (1 ml; 2.5  106 cells/ml) were
incubated (37°C in 5% CO2) for 30 min in RPMI 1640 medium (10% [wt/vol]
FCS) containing [3H]raltegravir (1 M; 0.2 Ci/ml) or the control ABCB1
substrate [3H]saquanavir (1 M; 0.2 Ci/ml). A separate incubation was under-
taken where the cells were preincubated prior to the substrate addition with
RPMI 1640 medium (10% [wt/vol] FCS) containing the potent noncompetitive
ABCB1 inhibitor tariquidar (300 nM for 30 min), which was also included during
the 30 min of substrate incubation. Following incubation, the cells were centri-
fuged (2,000 rpm at 1°C for 1 min), and 100 l supernatant aliquots were taken
and added to scintillation vials in order to calculate extracellular drug concen-
trations. The remaining supernatant was discarded, and the cells were washed
with ice-cold HBSS and centrifuged (2,000 rpm at 1°C for 1 min). This HBSS
wash was repeated a total of 3 times, after which the HBSS was discarded and
100 l tap water was added to lyse the cells. The incubations were vortexed for
5 min, and 100 l samples were added to scintillation vials. Four milliliters of
scintillation fluid was added to all the scintillation vials, which were then loaded
into a liquid scintillation analyzer (Tri-Carb). Using supernatant and intracellu-
lar radioactivity readings, cellular accumulation ratios (CARs) (ratio of drug in
the cell pellet compared with drug in the supernatant, assuming a 1 pl volume per
cell) were calculated for raltegravir and saquinavir in each cell line as described
previously (23).
Bidirectional transport of raltegravir using Caco-2 cell monolayers. Caco-2
monolayer experiments were performed as previously described (17), with slight
modifications. When confluent, Caco-2 cells (passage 30) were seeded onto
polycarbonate membrane transwells at a density of 5  105 cells/cm2. The
medium was replaced every 2 days, and plates were used in the experiments after
21 days. Monolayer integrity was checked by using a MillicellERS instrument
(Millipore) to determine the transepithelial electrical resistance (TEER) across
the monolayer. A TEER of 600 was deemed acceptable. On the day of the
experiment, the TEER was assessed, and the medium in each plate was replaced
with warm transport buffer (HBSS containing 25 mM HEPES and 0.1% [wt/vol]
bovine serum albumin [pH 7.4]) and allowed to equilibrate (37°C for 30 min).
For inhibition studies this transport buffer contained tariquidar (300 nM). The
transport buffer in the apical (for apical-to-basolateral transport) and basolateral
(for basolateral-to-apical transport) sides was replaced with transport buffer
containing either the test substrate [3H]raltegravir or the control ABCB1 sub-
strate [3H]digoxin (1 M; 0.33 Ci/ml) with or without 300 nM tariquidar.
Samples were taken from the receiver compartment at 30, 60, 90, 120, and 180
min and analyzed by using a liquid scintillation counter (Tri-Carb). Results were
used to determine the apparent permeability (Papp) (cm/s) for each direction and
the efflux ratio (ratio of basolateral-to-apical Papp to the apical-to-basolateral
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where dQ/dt is the change in the drug concentration in the receiver chamber over
time (nM/s), v is the volume in the receiver compartment (ml), A is the total
surface area of the transwell membrane (cm2), C0 is the initial drug concentra-
tion in the donor compartment (nM), and Papp is the apparent permeability
(cm/s).
Production of uptake transporter cRNA for Xenopus laevis oocyte injection.
SLCO1A2, SLCO1B1, and SLCO1B3 were cloned from cDNA extracted from
Huh-7D12 and A549 cells as described previously (15). IMAGE clones were
linearized and used as a template in cRNA production by using an mMessage
mMachine RNA transcription kit (Ambion) according to the manufacturer’s
protocol. SLC10A1, SLC15A1, and SLC15A2 cRNAs were provided by Becton
Dickinson (Oxford, United Kingdom).
X. laevis oocyte isolation, collagenase treatment, and microinjection. Oocytes
were harvested from sacrificed adult female X. laevis frogs and treated with
modified Barth’s solution minus calcium (88 mM NaCl, 1 mM KCl, 15 mM
HEPES, 100 U penicillin, 100 g streptomycin [pH 7.4]) containing collagenase
(1 mg/ml at 22°C in a 60-rpm shaker for 1 h). Cells were washed and transferred
into Barth’s solution containing calcium (88 mM NaCl, 1 mM KCl, 15 mM
HEPES, 0.3 mM CaCNO3  6H2O, 41 M CaCl2  6H2O, 0.82 mM
MgSO4  7H2O, 100 U penicillin, 100 g streptomycin [pH 7.4]) and stored in a
cold room at 8°C. Healthy cells were selected and injected with transporter
cRNA (50 ng per oocyte; 1 ng/nl) or sterile water (50 nl) and maintained in
Barth’s solution containing calcium to allow transporter expression (5 days for
SLCO1B3-injected oocytes and 3 days for all other conditions; 18°C). Barth’s
solution was replaced daily, and damaged oocytes were removed.
Drug accumulation in transporter RNA-injected X. laevis oocytes. Drug accu-
mulation studies using X. laevis oocytes were performed as described previously,
with slight modifications (15). Unless otherwise stated, radiolabeled drug was
incubated in Hanks balanced salt solution (pH 7.4) with 4 oocytes per condi-
tion in a 48-well Nunc flat-bottom plate (500 l; 0.33 Ci/ml; 1 M; room
temperature in a 60-rpm shaker for 1 h). Radiolabeled positive-control drugs
were tested alongside [3H]raltegravir to ensure successful transporter expression.
Positive-control drugs used were [3H]estrone-3-sulfate for SLCO1A2,
SLCO1B1, and SLCO1B3; [3H]aminohippuric acid for SLC22A6; [3H]tauro-
cholic acid for SLC10A1; [3H]glycyl sarcosine for SLC15A1 and SLC15A2; and
[14C]tetraethyl ammonium for SLC22A1. All incubations were terminated by
transferring the oocytes into cell strainers and washing them in ice-cold HBSS to
remove extracellular drug. Each oocyte was placed into a separate scintillation
vial followed by treatment with 100 l 10% SDS. After the disintegration of the
oocytes by the SDS treatment, 4 ml scintillation fluid was added to all vials, which
were then loaded into a liquid scintillation analyzer (Tri-Carb). Results are
expressed as the amount of drug per oocyte (pmol/oocyte), assuming that each
oocyte had a volume of 1 l (15). Results were obtained using oocytes from 2
X. laevis frogs.
Determination of raltegravir and tenofovir Km and Vmax using SLC22A6-
injected oocytes. The time-dependent SLC22A6-mediated transport of [3H]ralte-
gravir, [3H]tenofovir, and the control compound [3H]aminohippuric acid was
investigated by incubating each drug with SLC22A6- and H2O-injected oocytes
at a standard concentration of 1 M for various lengths of time (1, 2, 5, 10, 15,
30, 60, 120, 180, or 240 min). From these results, an incubation time was chosen
that gave a high accumulation rate in SLC22A6-injected oocytes compared to the
H2O-injected controls and also allowed enough radiolabeled drug to enter the
oocytes for it to be detectable. This time point was then used for kinetic exper-
iments in which [3H]raltegravir and [3H]tenofovir were incubated with
SLC22A6- and H2O-injected oocytes (1 h for both drugs) using a range of
concentrations (0.1, 0.3, 1, 3, 10, 30, 100, 300, and 1000 M for raltegravir and
0.3, 1, 3, 10, 30, 100, 200, and 300 M for tenofovir). Incubations were termi-
nated as described above. The transport of drug by SLC22A6 was determined by
subtracting the drug accumulation in H2O-injected oocytes from the drug accu-
mulation in SLC22A6-injected oocytes. The Km and Vmax were calculated by
plotting the initial rate of drug transport by SLC22A6 (pmol/oocyte/h) against
the drug incubation concentration (M). The intrinsic clearance (CLint) was
calculated by dividing the Vmax by the Km.
Determination of competition between raltegravir and tenofovir for SLC22A6
transport. [3H]raltegravir (0.33 Ci/ml; 1 M) was incubated for 1 h with
SLC22A6-injected oocytes with various concentrations of nonradiolabeled teno-
fovir (1, 3, 10, 30, 100, and 300 M), and the effect on [3H]raltegravir uptake was
determined. [3H]raltegravir (0.33 Ci/ml; 1 M) was also incubated with H2O-
injected cells with and without 300 M tenofovir in order to confirm the role
of SLC22A6. This experiment was repeated using [3H]tenofovir as the sub-
strate and nonradiolabeled raltegravir as the competitor drug using the same
concentration range and was terminated as described above. Fifty percent
inhibitory concentrations (IC50) were generated for both drugs by using
Prism 3.0.
Isolation of peripheral blood mononuclear cells from human blood. Venous
blood samples (60 ml) were obtained from healthy volunteers via venipuncture.
Blood was layered onto Ficoll-Paque Plus, and peripheral blood mononuclear
cells (PBMCs) were isolated by density gradient centrifugation according to the
manufacturer’s protocol. Cells were washed with ice-cold HBSS and centrifuged
(800  g at 1°C for 5 min). This HBSS wash was repeated a total of 3 times, after
which the HBSS was discarded and cells were resuspended in RPMI 1640
medium (10% [wt/vol] FCS) for use in experiments.
Cellular accumulation of raltegravir in peripheral blood mononuclear cells.
The accumulation of raltegravir in peripheral blood mononuclear cells was de-
termined by using the same method as that used with CEM and CEMVBL cells,
with slight modifications. Briefly, cells of a constant cell density (1 ml; 5  106
cells/ml) were incubated (37°C in 5% CO2) for 30 min in RPMI 1640 medium
(10% [wt/vol] FCS) containing [3H]raltegravir (1 M; 0.2 Ci/ml). Separate
incubations were undertaken where cells were preincubated prior to substrate
addition with RPMI 1640 medium (10% [wt/vol] FCS) containing either the
noncompetitive ABCB1 inhibitor tariquidar (300 nM for 30 min), the competi-
tive SLC22A6 inhibitor probenecid (1 mM for 30 min), or the competitive
SLC15A1 inhibitor glycyl sarcosine (1 mM for 30 min), which were also included
during the 30 min of substrate incubation. Cells were washed and treated for
analysis as described above for CEM and CEMVBL cells.
Cellular accumulation of raltegravir in primary renal proximal tubule epi-
thelial cells. When confluent, renal cells (passage 4) were seeded onto polyester
membrane transwells at a density of 5  105 cells/cm2. The medium was replaced
daily, and plates were used for experiments after 5 days. On the day of the
experiment, medium was replaced with buffered HBSS (25 mM HEPES [pH
7.4]) containing either [3H]raltegravir (1 M; 0.6 Ci/ml), [3H]tenofovir (1 M;
0.6 Ci/ml), or the control SLC22A6 substrate [3H]aminohippuric acid (1 M;
0.6 Ci/ml) and incubated (3 h at 37°C in 5% CO2). A separate incubation was
undertaken where the cells were preincubated prior to substrate addition with
buffered HBSS (25 mM HEPES [pH 7.4]) containing the SLC22A6 inhibitor
probenecid (1 mM for 30 min), which was also included during the 3 h of
substrate incubation. We also investigated the competition between raltegravir
and tenofovir by incubating [3H]raltegravir (1 M; 0.6 Ci/ml) with 100 M
tenofovir and [3H]tenofovir (1 M; 0.6 Ci/ml) with 100 M raltegravir (3 h at
37°C in 5% CO2). Once incubation was complete, an extracellular sample was
taken, and incubations were terminated by washing each well with cold HBSS
(4°C; 3 ml) three times to remove excess drug. Cells were lysed with 0.5 ml tap
water, and contents were analyzed by liquid scintillation as described above for
the CEM experiments.
Determination of transporter mRNA expression in primary renal proximal
tubule cells and whole kidney. mRNA from primary renal proximal tubule cells
were isolated by using Tri reagent according to the manufacturer’s protocol.
mRNA was then reverse transcribed by using the TaqMan reverse transcription
kit according to the manufacturer’s protocol. Real-time PCR using TaqMan
array plates was combined with cDNA (40 ng) and used to quantify mRNA
expression by standard methodologies. This process was repeated, and mRNA
quantification was obtained for whole kidneys purchased from Ambion (United
Kingdom), which was created from a pool of three individuals. Transporters were
quantified by using the CT method and included SLC22A6, SLC22A1,
SLC22A2, SLC22A3, ABCC1, ABCC2, ABCC3, ABCC4, and ABCC10. Glyc-
eraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the housekeep-
ing gene.
Statistical analysis. Data were analyzed by using SPSS 13.0 for Windows. All
data were tested for normality by using the Shapiro-Wilk test. An independent t
test was used to determine the significance of the ABCB1 flow cytometry data,
Caco-2 transwell data, PBMC accumulation data, and renal cell accumulation
data. The Mann-Whitney U test was used for all other data. A two-tailed P value
of 	0.05 was accepted as being statistically significant.
RESULTS
Toxicity of raltegravir in CEM and Caco-2 cell lines. Ralte-
gravir was not cytotoxic in CEM or Caco-2 cell lines at the
tested concentrations. Cell viability (percent mean viability
compared to the drug-free control  SD; n  6) was unaf-
fected by concentrations of up to 100 M in the Caco-2
(104.9%  12.7%) and CEM (113.9%  13.0%) cell lines. A
concentration of 1 M raltegravir was used in subsequent
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experiments with these cells to minimize the risk of transporter
saturation, as previously recommended (17).
ABCB1 expression levels in CEM and CEMVBL100 cell lines.
The expression of ABCB1 in CEM and CEMVBL100 cell lines
was determined by using flow cytometry. CEMVBL100 cells had
a significantly higher level of ABCB1 cell surface expression
(relative fluorescence  246.7  9.3; P 	 0.001) than in CEM
cells (relative fluorescence  1.5  0.5).
Effect of the ABCB1 inhibitor tariquidar on the accumula-
tion of raltegravir and saquinavir using CEM and CEMVBL100
cell lines. The cellular accumulation of [3H]raltegravir was de-
termined with CEM and ABCB1-overexpressing CEMVBL100
cells, and the effect of the ABCB1 inhibitor tariquidar on this
accumulation was investigated (Fig. 1A). The level of
[3H]raltegravir accumulation was lower in CEMVBL100 cells
(CAR  1.4  0.2) than in CEM cells (CAR  2.1  0.2; P 
0.02). This difference was reversed when CEMVBL100 cells
were treated with tariquidar (CAR  2.0  0.4). The control
ABCB1 substrate [3H]saquinavir had a lower level of accumu-
lation in CEMVBL100 cells (CAR  19.0  5.6) than in CEM
cells (CAR  37.5  2.1; P  0.02) (Fig. 1B). This difference
was also reversed when CEMVBL100 cells were treated with
tariquidar (CAR  37.8  8.5).
Effect of the ABCB1 inhibitor tariquidar on the bidirec-
tional transport of raltegravir and digoxin using a Caco-2
monolayer. The Papp values obtained for [
3H]raltegravir and
[3H]digoxin with and without tariquidar are given in Fig. 1C.
All Papp and efflux ratio calculations were made by using the
samples taken after 120 min of incubation as sink conditions
were maintained. [3H]raltegravir showed significantly higher
transport in the B3A direction (Papp  13.4  10

6  2.1 
10




6; P  0.02). The efflux ratio (B3A/A3B) of
[3H]raltegravir at 120 min was 1.9. The presence of tariquidar
reduced the efflux ratio of [3H]raltegravir to 1.3 (P  0.30).
The control compound [3H]digoxin showed significantly higher
levels of transport in the B3A direction (Papp  12.9 
10
6  0.6  10
6) compared to the A3B direction (Papp 
2.1  10
6  0.3  10
6; P 	 0.001). The efflux ratio of
[3H]digoxin at 120 min was 6.3. The presence of tariquidar
reduced the efflux ratio of [3H]digoxin to 0.9 (P  0.58).
Accumulation of raltegravir in oocytes by uptake transport-
ers. [3H]raltegravir transport by the investigated uptake trans-
porters is given in Table 1. The level of [3H]raltegravir accu-
mulation was significantly higher in SLC22A6-injected oocytes
(0.44  0.12 pmol/oocyte; n  18) than in H2O-injected oo-
cytes (0.20  0.05 pmol/oocyte; n  19; P 	 0.001). [3H]ralte-
gravir accumulation was also significantly higher in SLC15A1-
injected oocytes (0.26  0.12 pmol/oocyte; n  19) than in
H2O-injected oocytes (0.17  0.03 pmol/oocyte; n  19; P 
0.003). The positive-control compounds [3H]estrone-3-sulfate,
[3H]aminohippuric acid, [3H]-taurocholic acid, [3H]glycyl sar-
cosine, and [14C]tetraethyl ammonium all showed significant
increases in levels of accumulation in transporter RNA-in-
jected oocytes compared to H2O-injected oocytes.
TABLE 1. Accumulation of 1 M raltegravir and various positive-
control compounds in oocytesa
Transporter Drug
Mean drug concn (pmol/









SLCO1A2 RAL 0.39  0.14 0.35  0.07 1.11 (0.09)
E3S 1.48  0.63 0.27  0.09 5.48 (	0.01)
SLCO1B1 RAL 0.41  0.05 0.38  0.05 1.08 (0.09)
E3S 2.68  1.55 0.34  0.17 7.97 (	0.01)
SLCO1B3 RAL 0.63  0.19 0.65  0.13 0.97 (0.09)
E3S 0.56  0.23 0.21  0.03 2.60 (	0.01)
SLC22A6 RAL 0.44  0.12 0.20  0.03 2.22 (	0.01)
AHA 9.39  2.64 0.17  0.04 56.9 (	0.01)
SLC10A1 RAL 0.20  0.03 0.20  0.03 1.03 (0.57)
TCA 0.28  0.10 0.08  0.05 3.51 (	0.01)
SLC15A1 RAL 0.26  0.12 0.17  0.03 1.52 (	0.01)
GLY 0.45  0.13 0.11  0.05 4.22 (	0.01)
SLC15A2 RAL 0.19  0.04 0.17  0.03 1.08 (0.16)
GLY 0.29  0.19 0.11  0.05 2.69 (	0.01)
SLC22A1 RAL 0.21  0.03 0.17  0.04 1.21 (0.06)
TEA 0.34  0.06 0.17  0.04 1.99 (	0.01)
a Results are expressed as the mean drug concentrations per oocyte (pmol/
oocyte) (n  2 biological replicates; n  4 experimental replicates per biological
replicate)  standard deviations. Also shown are the ratios of drug accumulation
between transporter RNA-injected and H2O-injected oocytes. RAL, raltegravir;
E3S, estrone-3-sulfate; AHA, amminohippuric acid; TCA, taurocholic acid;
GLY, glycyl sarcosine; TEA, tetraethyl ammonium.
FIG. 1. (A) [3H]raltegravir (1 M) accumulation in CEM,
CEMVBL100, and CEMVBL100 cells treated with 300 nM tariquidar.
(B) [3H]saquinavir (1 M) accumulation in CEM, CEMVBL100, and
CEMVBL100 cells treated with 300 nM tariquidar. Data in A and B are
expressed as mean CARs (n  4 biological replicates; n  4 experi-
mental replicates per biological replicate)  SD. *, P 	 0.05; **, P 	
0.01; ***, P	 0.001. (C) Apparent permeability of [
3H]raltegravir and
[3H]digoxin in the A-to-B (apical-to-basolateral) and B-to-A (basolat-
eral-to-apical) directions across the Caco-2 transwell membrane, with
and without the presence of 300 nM tariquidar. Data are expressed as
mean apparent permeabilities (10
6 cm/s; n  3 experimental rep-
licates)  SD. *, P 	 0.05; **, P 	 0.01; ***, P 	 0.001.
882 MOSS ET AL. ANTIMICROB. AGENTS CHEMOTHER.
Determination of the time-dependent accumulation of ralte-
gravir, tenofovir, and aminohippuric acid in SLC22A6-in-
jected oocytes. All drugs tested had a greater accumulation
rate in SLC22A6-injected oocytes than in H2O-injected oo-
cytes (Fig. 2A, B, and C). [3H]raltegravir concentrations con-
tinued to increase in SLC22A6-injected oocytes throughout
the 4-h incubation period, whereas saturation was reached in
H2O-injected oocytes after 2 h. Both [
3H]tenofovir and
[3H]aminohippuric acid showed virtually no accumulation in
H2O-injected oocytes.
Determination of raltegravir and tenofovir Km and Vmax
values using SLC22A6-injected oocytes. An incubation time of
1 h was chosen for subsequent kinetic studies. [3H]raltegravir
and [3H]tenofovir kinetics were determined for SLC22A6 in
the oocyte expression system (Fig. 2D and E). The raltegravir
Km and Vmax were calculated to be 150 M and 36 pmol/
oocyte/h, respectively. The raltegravir CLint (Vmax/Km) was cal-
culated to be 0.2 l/oocyte/h. The tenofovir Km and Vmax were
calculated to be 25 M and 129 pmol/oocyte/h, respectively.
The tenofovir CLint was calculated to be 5.2 l/oocyte/h.
Competition between raltegravir and tenofovir for SLC22A6
transport. When incubated at 1 M for 1 h, [3H]raltegravir
showed a significantly higher level of accumulation in
SLC22A6-injected oocytes than in H2O-injected oocytes
(1.73  0.46 pmol/oocyte versus 0.54  0.06 pmol/oocyte; n 
5; P  0.014) (Fig. 3A). The coincubation of [3H]raltegravir
with 1, 3, 10, 30, 100, and 300 M tenofovir resulted in levels
of [3H]raltegravir accumulation in SLC22A6-injected oocytes
of 1.78  0.41 pmol/oocyte, 1.63  0.62 pmol/oocyte, 1.48 
0.58 pmol/oocyte, 1.28  0.27 pmol/oocyte, 0.96  0.28
pmol/oocyte, and 0.83  0.31 pmol/oocyte, respectively (Fig.
3C). There was a statistically significant decrease (P 	 0.05) in
the level of [3H]raltegravir accumulation when concentrations
of 100 M tenofovir and higher were added to the incubation
mixture.
Similar results were seen when [3H]tenofovir accumulation
was investigated in the presence of various concentrations of
raltegravir. When incubated at 1 M for 1 h, [3H]tenofovir
showed a significantly higher level of accumulation in
SLC22A6-injected oocytes than in H2O-injected oocytes
(2.11  0.37 pmol/oocyte versus 0.03  0.01 pmol/oocyte; n 
5; P	 0.009) (Fig. 3B). The coincubation of [3H]tenofovir with
1, 3, 10, 30, 100, and 300 M raltegravir resulted in levels of
[3H]tenofovir accumulation in SLC22A6-injected oocytes of
FIG. 2. (A) SLC22A6- and H2O-injected oocyte uptake of [
3H]raltegravir over a 4-h incubation period. (B) SLC22A6- and H2O-injected oocyte
uptake of [3H]tenofovir over a 4-h incubation period. (C) SLC22A6- and H2O-injected oocyte uptake of [
3H]aminohippuric acid over a 4-h
incubation period. Data in A, B, and C are expressed as mean drug accumulations (pmol/oocyte) (n 5 experimental replicates from one biological
replicate)  standard errors (SE). (D) Concentration dependency of the uptake of [3H]raltegravir by SLC22A6. (E) Concentration dependency
of the uptake of [3H]tenofovir by SLC22A6. Data in D and E are expressed as mean rates of [3H]tenofovir transport (pmol/oocyte/h) (n  4
experimental replicates from one biological replicate)  SE.
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2.11  0.14 pmol/oocyte, 2.07  0.38 pmol/oocyte, 1.47  0.43
pmol/oocyte, 0.78  0.50 pmol/oocyte, 0.49  0.06 pmol/oo-
cyte, and 0.28  0.08 pmol/oocyte, respectively (Fig. 3D).
There was a statistically significant decrease (P 	 0.05) in
levels of [3H]tenofovir accumulation when concentrations of
10 M raltegravir and higher were added to the incubation
mixtures.
Effect of transporter inhibitors on the accumulation of ralte-
gravir in peripheral blood mononuclear cells. The cellular
accumulation of [3H]raltegravir in peripheral blood mononu-
clear cells was determined (CAR  3.02  0.67) (Fig. 4A).
Cellular accumulation was not significantly altered by coincu-
bation with tariquidar (CAR  3.78  1.56; P  0.77), pro-
benecid (CAR  3.26  0.98; P  0.77), or glycyl sarcosine
(CAR  3.23  0.83; P  0.56).
Interactions in primary renal proximal tubule epithelial
cells. The levels of cellular accumulation of [3H]raltegravir
(CAR  2.01  0.20) (Fig. 4B), [3H]tenofovir (CAR  3.45 
0.76) (Fig. 4C), and [3H]aminohippuric acid (CAR  0.50 
0.02) (Fig. 4D) in renal proximal tubule epithelial cells were
determined. [3H]raltegravir cellular accumulation was not sig-
nificantly altered by treatment with 1 mM probenecid (CAR 
2.19  0.45; P  0.56) or 100 M tenofovir (CAR  2.07 
0.08; P  0.66). [3H]tenofovir showed a high level of cellular
accumulation, which was not significantly altered by treatment
with 1 mM probenecid (CAR  2.59  0.56; P  0.19) or 100
M raltegravir (CAR  3.15  0.74; P  0.65). For [3H]ami-
nohippuric acid there was a trend toward a lower level of
cellular accumulation when incubated with 1 mM probenecid
(CAR  0.44  0.03; P  0.08).
Transporter expression in primary renal proximal tubule
cells versus whole kidneys. All transporters tested showed
lower or undetectable levels of expression in primary renal
proximal tubule cells compared to whole kidney (Fig. 4E).
Importantly, SLC22A6 was undetectable in primary renal cells.
DISCUSSION
The results from CEM/CEMVBL accumulation and Caco-2
bidirectional transport experiments confirm that raltegravir is
transported by ABCB1. The extent of raltegravir transport by
ABCB1 was small compared to the transport of the positive
controls saquinavir and digoxin. Indeed, FDA guidelines rec-
ommend that a drug should achieve an efflux ratio of at least 2
in Caco-2 cell monolayers and show greater than a 50% re-
duction in the efflux ratio when an ABCB1 inhibitor is used in
order for ABCB1 transport to be considered relevant in vivo
(16). In our Caco-2 experiment raltegravir achieved an efflux
ratio of only 1.9 and a reduction of 32% when tariquidar was
used to inhibit ABCB1. The low rate of raltegravir transport by
ABCB1 may explain the absence of major drug interactions
with known potent ABCB1 inhibitors. This is consistent with a
FIG. 3. (A) Accumulation of 1 M [3H]raltegravir in SLC22A6- and H2O-injected oocytes with and without the addition of 300 M
tenofovir. (B) Accumulation of 1 M [3H]tenofovir in SLC22A6- and H2O-injected oocytes with and without the addition of 300 M
raltegravir. Data in A and B are expressed as mean drug concentrations per oocyte (pmol/oocyte) (n  5 experimental replicates from one
biological replicate)  SE. *, P 	 0.05; **, P 	 0.01; ***, P 	 0.001. (C) Determination of IC50 for inhibition of 1 M [
3H]raltegravir
SLC22A6 transport by tenofovir. Data are expressed as mean [3H]raltegravir oocyte concentrations (pmol/oocyte) (n  5 experimental
replicates from one biological replicate)  SE. (D) Determination of IC50 for inhibition of 1 M [
3H]tenofovir SLC22A6 transport by
raltegravir. Data are expressed as mean [3H]tenofovir oocyte concentrations (pmol/oocyte) (n  5 experimental replicates from one
biological replicate)  SE.
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previous report that the coadministration of low-dose ritonavir
had no major effect on raltegravir pharmacokinetics, and no
dose adjustment is required for patients (22).
Raltegravir showed significantly increased levels of accumu-
lation in SLC15A1- and SLC22A6-injected oocytes compared
to H2O-injected controls, but accumulation was not higher
in oocytes expressing SLCO1A2, SLCO1B1, SLCO1B3,
SLC15A2, and SLC10A1. In SLC22A6-injected oocytes, both
raltegravir and tenofovir inhibited the accumulation of the
other in a concentration-dependent manner (Fig. 3C and D).
No competition was observed for H2O-injected oocytes, which
supports the hypothesis that raltegravir and tenofovir are com-
peting for SLC22A6 transport and are not having nonspecific
effects on oocyte membrane permeability. IC50 values of 27.3
M and 14.0 M were determined for tenofovir and raltegra-
vir, respectively. The IC50 obtained for raltegravir was much
lower than the observed Km for SLC22A6 (IC50 of 14.0 M
versus a Km of 147 M). These results suggest that raltegravir
is a more efficient SLC22A6 inhibitor than it is a substrate.
Previous studies indicated that SLC22A6 and SLC15A1 are
absent from PBMCs (5), and so these transporters are unlikely
to explain the unusual PK-PD relationship for raltegravir. In-
deed, our studies of PBMCs with known inhibitors of ABCB1,
SLC22A6, and SLC15A1 revealed no significant interaction
with raltegravir.
Wenning et al. (38) previously studied the interaction of
raltegravir (400 mg twice daily) and tenofovir (300 mg once
daily). The study showed increased raltegravir AUC (49%) and
Cmax (64%) values but no effect on the raltegravir Cmin and a
decrease in the tenofovir AUC (10%), Cmax (23%), and Cmin
(13%) (38). SLC22A6 is expressed predominantly in the prox-
imal tubule of the kidney on the basolateral (blood-facing)
surface, thereby facilitating the removal of drugs out of the
blood and into the urine (31). Therefore, a possible mechanism
of interaction is the inhibition of SLC22A6-mediated raltegra-
vir transport at the kidney-proximal tubule by tenofovir, result-
ing in increased raltegravir plasma concentrations. In order to
investigate interactions at the level of the kidney, we conducted
a number of experiments with primary renal proximal cells. No
interaction between tenofovir and raltegravir was observed for
these cells, but neither was an interaction with the positive-
control substrate and inhibitor. Subsequent analyses revealed
the expression of SLC22A6 to be undetectable, unlike kidney
tissue. Furthermore, all transporters that were assessed were at
lower levels of expression than in kidney tissue, and the ab-
sence of a robust primary cell model for these studies is a
limitation.
Since only a small percentage (around 30%) of raltegravir
excreted via the kidney is in the parent form, with the remain-
ing 70% being the glucuronide metabolite (24), it is important
to determine if the raltegravir glucuronide is also transported
by SLC22A6 and inhibited by tenofovir. It would also be in-
teresting to investigate the transport and inhibitory potential of
tenofovir diphosphate for SLC22A6 and whether this affects
raltegravir transport to the same degree.
The Xenopus laevis oocyte expression system has several
advantages when investigating drug transport. The large size
and high level of protein production of oocytes provide robust
and reliable data. Also, the level of expression of endogenous
primary and secondary active xenobiotic transporters in oo-
cytes is low (32). However, there are also disadvantages. The
temperature must be maintained at 18°C during protein ex-
pression and at around room temperature during any accumu-
lation experiments to avoid degradation, and this may impact
transporter kinetics. Also, as in other models, the expression of
the investigated transporters is superphysiological. Therefore,
although they allow an investigation of low-affinity or high-
permeability substrates, this means that caution should be
taken when extrapolating the data to in vivo observations.
In summary, our studies have shown raltegravir to have
minimal interactions with known drug transporters. Raltegra-
vir is transported by ABCB1 in vitro, although the rate of
transport is low and the potential for interactions is expected to
be small. Raltegravir is a substrate for SLC22A6 and SLC15A1
in X. Laevis oocyte expression systems and competes with
tenofovir for SLC22A6 transport. Polymorphisms in SLC22A6
FIG. 4. (A) [3H]raltegravir (1 M) accumulation in peripheral
blood mononuclear cells alone or treated with 300 nM tariquidar, 1
mM probenecid, or 1 mM glycyl sarcosine. (B) [3H]raltegravir (1 M)
accumulation in primary renal proximal tubule cells alone or treated
with 1 mM probenecid or 100 M tenofovir. (C) [3H]tenofovir (1 M)
accumulation in primary renal proximal tubule cells alone or treated
with 1 mM probenecid or 100 M raltegravir. (D) [3H]aminohippuric
acid (1 M) accumulation in primary renal proximal tubule cells alone
or treated with 1 mM probenecid. Data in A, B, C, and D are expressed
as mean CARs (n  3 experimental replicates)  SD. *, P 	 0.05; **,
P 	 0.01; ***, P 	 0.001. (E) Relative abundance of transporter RNA
in cultured renal proximal tubule cells compared to transporter RNA
in whole kidney (log percent) (n  1 experimental replicate).
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have previously been described and now warrant study in the
context of raltegravir.
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